Delphinus relocates headquarters, triples size of facility
Move Anticipates Expansion, Advances Company Initiatives
Delphinus Medical Technologies, Inc., the leader in advanced breast ultrasound technology, has announced that it is relocating its corporate headquarters from Plymouth Township, Mich., to Novi, Mich., this week. The new headquarters is nearly triple the size of its prior location, allowing Delphinus to expand its staff, dedicate more space to research and development, and prepare for commercialization of SoftVue™, a whole breast ultrasound system that allows physicians to image the entire breast for diagnostic imaging purposes.*
The expansion is the latest in a recent series of achievements for the company. In December 2015, on the heels of an unprecedented Series C venture round of $40 million, Delphinus added two new senior-level advisors to its Board of Directors, as well as a new vice president of quality and regulatory affairs.
“Our new corporate headquarters in Novi reinforces Delphinus’ commitment to transforming early detection of breast cancer and expands our presence in the Michigan community. Our growth from 7,500 to 21,000 square feet is a significant expansion that will allow us to increase our lab space, double our headcount and significantly advance our R&D capability,” said Mark J. Forchette, president and CEO of Delphinus. “This new facility will provide a fantastic environment for our team as we concentrate on our one and only focus: transforming early detection of breast cancer
with our breakthrough SoftVue imaging technology.”
Delphinus expects its new corporate headquarters to attract frequent visits from healthcare leaders, customers and vendors, so the company has focused on designing the facility to maximize functionality. One of the additions to the new facility will be a dedicated demonstration room that will allow the company to showcase SoftVue™ and image review to site visitors.
As an ultrasound technology, SoftVue™ offers the potential to not only assist physicians in finding more cancers, but also to reduce the false positive rates that have troubled other breast imaging techniques. SoftVue™’s unparalleled, sophisticated design incorporates a circular ultrasound transducer featuring proprietary TriAD™ (triple acoustic detection) technology that is unique to medical imaging. This multi-dimensional advancement presents cross-sectional ultrasound slices through the entire volume of breast tissue, capturing not only reflected echoes in a 360-degree array, but also signals passing through the breast, depicting tissue characterization.
About Delphinus Medical Technologies, Inc.
Headquartered in Plymouth, Mich. with a satellite office in Sunnyvale, Calif., Delphinus Medical Technologies, Inc. is a pioneering medical imaging company that has developed SoftVue™, the first circular array transducer technology that has received sequential U.S. Food and Drug Administration clearances. The patented technology is a whole breast ultrasound imaging device that delivers no radiation, requires no compression, and images the entire breast with a single scan. SoftVue™ is indicated for use as a B-mode ultrasonic imaging system and is not intended to be used as a replacement for screening mammography. Delphinus was founded as a spin out of the Karmanos Cancer Institute in Detroit and is capitalized through principal investments by Arboretum Ventures, Ann Arbor, Mich., Beringea, Farmington Hills, Mich., North Coast Technology Investors, Ann Arbor, Mich., Venture Investors, Madison, Wis., Hopen Life Science Ventures, Grand Rapids, Mich., and Waycross Ventures, Menlo Park, Calif. For more information, visit www.delphinusmt.com.
SoftVue™ is indicated for use as a B-mode ultrasonic imaging system and is not intended to be used as a replacement for screening mammography.
Nobles Global Communications
Email: [email protected]